bimagrumab and semaglutide Trial suggests GLP-1 combo therapy cuts fat while preserving muscle in obesity Antibody blockade of activin type
Description
The dominance of oestrone and loss of 17-oestradiol might underlie the increased prevalence of hormone-responsive breast cancer after menopause, particularly in the context of obesity
Gradual tapering
Experiments and modelling identify the rupture of mechanically integrated cells as a key toughening mechanism
Most side effects diminish within weeks as the body adapts
This same mechanism may explain why tirzepatide (which also activates GIP) has lower nausea rates than semaglutide
This is not endorsed by the NHS or NICE
